Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Medivir reshapes discovery
November 2007
SHARING OPTIONS:

MILFORD, Mass.—Swedish-based biotechnology firm Medivir AB has chosen the Waters Synapt high-definition mass spectrometry (HDMS) system to hasten its drug discovery efforts in the area of protease inhibitor research and eventually help patients who suffer with herpes, hepatitis C, HIV, osteoporosis, osteoarthritis and high blood pressure. Installed in June, the Synapt system is said to be yielding significant information that is assisting with the decision-making process and Medivir's efforts to reach its drug discovery milestones.
"Medivir is constantly reviewing opportunities to improve research output both in terms of quantity and quality. This investment in the Waters Synapt HDMS instrument has been seen as a very important vehicle to increase research output and to provide high-quality support for the discovery disciplines," says Dr. Bertil Samuellson, Medivir's vice president of discovery research.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.